

# The *ahpC* c–54t compensatory mutation is not always a valid surrogate for isoniazid resistance in *Mycobacterium tuberculosis*

Viktória Szél,<sup>1</sup> Jody E. Phelan,<sup>2</sup> Sophia B. Georgiou,<sup>3</sup> David L. Dolinger,<sup>4</sup> Taane G. Clark,<sup>2</sup> Stefan Niemann,<sup>5,6</sup> Lilla K. Lőrinczi,<sup>1</sup> Claudio U. Köser<sup>7</sup>

**AUTHOR AFFILIATIONS** See affiliation list on p. 3.

**ABSTRACT** Thirteen commercial genotypic antimicrobial susceptibility assays interrogate mutations upstream of *ahpC* to infer isoniazid resistance for *Mycobacterium tuberculosis*. We demonstrate that relying on one of these compensatory mutations (i.e., *ahpC* c–54t)—rather than causative resistance mutations in *katG* that *ahpC* compensates for—can result in systematic false-resistant results for isoniazid with the Cepheid Xpert MTB/XDR and suboptimal treatment. The WHO mutation catalog should be refined to address this scenario.

**KEYWORDS** *Mycobacterium tuberculosis*, isoniazid, genotypic antimicrobial susceptibility testing, *ahpC*, Cepheid Xpert MTB/XDR

With a global prevalence of 11% (95% CI 9–13), isoniazid-resistant, rifampicin-susceptible tuberculosis (Hr-TB) affects approximately three times more new tuberculosis patients than rifampicin-resistant TB (1). Hr-TB treatment requires the inclusion of levofloxacin for 6 months (1).

Cepheid Xpert MTB/XDR (Table 1) is the only WHO-recommended low-complexity automated assay for isoniazid genotypic antimicrobial susceptibility testing (gAST) (2). It analyses two *inhA* promoter regions, responsible for low-level isoniazid and ethionamide/prothionamide cross-resistance, as well as the *katG* codon 315, the most common mechanism of high-level isoniazid resistance (2). Diagnostic sensitivity is further enhanced by targeting the *ahpC* promoter region. Unlike *inhA* and *katG* mutations, mutations that result in the over-expression of *ahpC* act as compensatory mechanisms for fitness defects caused by *katG* mutations rather than directly causing resistance (i.e., they can infer isoniazid resistance when used as surrogates for *katG* resistance mutations outside of the codon 315 region) (3). Notably, the current edition of the WHO mutation catalog does not recognize any *ahpC* mutations as resistance markers of isoniazid because of limitations in its classification algorithm (4). This creates a paradox where a sample may be classified as genotypically resistant due to *ahpC* by the Xpert MTB/XDR but cannot be confirmed by whole genome sequencing (WGS) unless a known *katG* resistance mutation is also present.

In 2023, the Hungarian National Reference Laboratory for Mycobacteriology received a smear-positive sputum sample that was genotypically susceptible to rifampicin, isoniazid, and ethionamide/prothionamide based on the Bruker/Hain Lifescience GenoType MTBDR<sub>plus</sub> VER 2.0 assay, which does not interrogate *ahpC* (2). The isolate was phenotypically pan-susceptible to all first- and second-line drugs tested, including isoniazid (see Supplementary methods).

A subsequent bronchial aspirate from the same patient was rifampicin-susceptible by Cepheid Xpert MTB/RIF Ultra. Xpert MTB/XDR classified this sample as mono-isoniazid-resistant due to an *ahpC* mutation, even though it was later found to be phenotypically susceptible to isoniazid as well as rifampicin, ethambutol, and streptomycin using the

**Editor** Jared A. Silverman, Bill and Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA

Address correspondence to Claudio U. Köser, [cuk21@cam.ac.uk](mailto:cuk21@cam.ac.uk).

Viktória Szél and Jody E. Phelan contributed equally to this article. Viktória Szél was listed first because she initiated this study after noticing the discordant results.

J.E.P. has worked as a consultant for the Johnson & Johnson Center for Global Health Discovery at the London School of Hygiene & Tropical Medicine (London, UK). S.B.G. worked as a consultant for FIND (Grand-Saconnex, Switzerland). D.L.D. provides consulting services for Bigtec Labs (Bengaluru, India), Integrated Quality Laboratory Services (Lille, France), Médecins Sans Frontières (Paris, France), and the TB Alliance (New York, NY, USA). D.L.D. serves as an expert advisor to the Institute of Tropical Medicine Antwerp-Innovation Advisory Council (Antwerp, Belgium) and is on the board of AALFA (Brussels, Belgium). C.U.K. is a consultant for Becton Dickinson (Franklin Lakes, NJ, USA), the IRCCS San Raffaele Scientific Institute (Milan, Italy), and the TB Alliance (New York, NY, USA). C.U.K.'s consulting for Becton Dickinson involves a collaboration with Janssen (Beerse, Belgium) and Thermo Fisher Scientific (Waltham, MA, USA). C.U.K. worked as a consultant for FIND (Grand-Saconnex, Switzerland), the Stop TB Partnership (Geneva, Switzerland), the WHO Global TB Programme (Geneva, Switzerland), and the WHO Regional Office for Europe (Copenhagen, Denmark). C.U.K. collaborated with PZA Innovation (Baltimore, MD, USA). C.U.K. is or was an unpaid advisor to Bigtec Labs (Bengaluru, India), Cepheid (Sunnyvale, CA, USA), and Genoscreen (Lille, France); GenoScreen covered related travel and accommodation expenses only. The other authors declared no conflict of interest.

See the funding table on p. 3.

**Received** 16 February 2025

**Accepted** 20 March 2025

**Published** 22 April 2025

Copyright © 2025 Szél et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**TABLE 1** Commercial gDST assays that interrogate *ahpC*

Approved for diagnostic use in <sup>a</sup>	Assay
European Union <sup>b</sup>	Cepheid Xpert MTB/XDR <sup>c</sup>
	Eudicpia EuDx MDR TB Detection Kit (5)
	GenoScreen Deeplex Myc-TB <sup>c</sup>
	ShengTing TBseq (6)
	Ustar Biotechnologies MultNAT MTC/MDR Assay (7)
	YD Diagnostics MolecuTech REBA MTB-MDR (8)
	Zeasat Biotech MeltPro MTB/INH (9)
	Zeasat Biotech MeltPro MTB/MDR (10)
	Zeasat Biotech Sanity 2.0 MDR-TB Test Kit (11)
	Zeasat Biotech Sanity 2.0 MTB/MDR Test Kit (12)
Republic of Korea	Invitros AdvanSure MDR-TB GenoBlot Assay (13)
Russian Federation	BIOCHIP-IMB TB-Biochip-1 (14)
	BIOCHIP-IMB TB-TEST (15)

<sup>a</sup>Assays may be approved for diagnostic use in additional countries.

<sup>b</sup>CE-IVD.

<sup>c</sup>WHO-recommended (2).

BD MGIT system. Faced with this discordance, isoniazid was removed and, contrary to WHO guidelines, not replaced with levofloxacin, resulting in a regimen of only rifampicin, ethambutol, and pyrazinamide (1). After 2 months of treatment in Hungary, the patient returned to their home country for further treatment.

Subsequent Xpert MTB/XDR testing of the initial culture confirmed genotypic isoniazid mono-resistance. WGS identified the isolate (European Nucleotide Archive accession: ERR13111154) as belonging to lineage 4.1.2.1, a subgroup of the globally widespread Haarlem genotype (16), and carrying a c-54t mutation upstream of the *ahpC* start codon (Table S1). This mutation, located 12 nucleotides upstream of the transcriptional start site, falls within the *ahpC* region targeted by Xpert MTB/XDR, which correctly reported the sample as mutated. Because of the aforementioned limitation of the WHO mutation catalog, this mutation is classified as having uncertain significance, which is also the interpretation provided by the WHO-recommended GenoScreen Deeplex Myc-TB targeted next-generation sequencing gAST assay (Table 1; Alice Ferré, personal communication) (4). Nevertheless, strong experimental evidence from multiple laboratories indicates that this mutation causes *ahpC* overexpression and should, in principle, be a viable surrogate for inferring isoniazid resistance (17–20).

Analysis of ERR13111154 alongside 11,953 other lineage 4.1.2.1 genomes revealed 11 genomes (0.09%) with c-54t as the sole *ahpC* promoter mutation (Table S1). Of these, four also had a *katG* Ser315Thr mutation, and six carried other resistance *katG* mutations (Table S1) (4). Only ERR13111154 lacked mutations in *katG* or its upstream region, resulting in a positive predictive value of *ahpC* c-54t for genotypic isoniazid resistance of 91% (95% CI 59–100) in lineage 4.1.2.1. This is consistent with the positive predictive value of 93% (95% CI 82–100) for phenotypic isoniazid resistance reported by WHO based on a more comprehensive analysis across lineages, suggesting that *ahpC* c-54t is usually a good surrogate for isoniazid resistance (4, 21).

Two hypotheses were explored to explain the discordance with ERR13111154. First, loss-of-function mutations in *ahpC* could theoretically negate the effect of the promoter mutation, similar to how WHO has recognized that *eis* promoter mutations cannot confer amikacin resistance if *eis* is inactive (4, 22). However, no evidence of such epistasis was found (Fig. S1; Table S1). Second, we considered whether an ancestor of ERR13111154 had been isoniazid-resistant due to a *katG* mutation before acquiring the *ahpC* compensatory mutation and then reverting to a susceptible phenotype because of the associated fitness cost (i.e., reverting to wild-type *katG* sequence but retaining the *ahpC* mutation) (22). Phylogenetic analysis found no evidence to support this scenario (Fig. S1; Table S1).

In summary, reliance on compensatory mechanisms such as *ahpC* mutations—rather than causative resistance mutations—can in rare cases lead to systematic false-resistant results and suboptimal treatment decisions. This is relevant for at least 11 other commercial gAST assays that are approved for diagnostic use and interrogate *ahpC* (Table 1) as well as routine WGS diagnostic services globally. These findings highlight the need for revised, evidence-based guidance on *ahpC* in the next edition of the WHO mutation catalog and on how to resolve discordant AST results more generally (2, 23).

ACKNOWLEDGMENTS

We thank A. Ferré (GenoScreen, Lille, France) for sharing information about the Deeplex assay and S. Laurent (FIND, Grand-Saconnex, Switzerland) for his analysis of ERR13111154.

T.G.C. is supported by the UK Research and Innovation (BBSRC BB/X018156/1; MRC MR/X005895/1 and EPSRC EP/Y018842/1). S.N. is supported by the German Ministry of Health through the SubSaharanSeqNet project (ZMVI1-2519GHP708), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—EXC 2167 Precision Medicine in Inflammation and the Research Training Group 2501 TransEvo, and the Leibniz Science Campus Evolutionary Medicine of the Lung (EvoLUNG). C.U.K. is a visiting scientist at the Department of Genetics, University of Cambridge, and a senior member at Wolfson College, University of Cambridge.

AUTHOR AFFILIATIONS

- <sup>1</sup>National Reference Laboratory for Mycobacteriology, National Koranyi Institute of Pulmonology, Budapest, Hungary
- <sup>2</sup>Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
- <sup>3</sup>End TB Dx Consulting LLC, San Diego, California, USA
- <sup>4</sup>DLD IVD Consulting LLC, Medway, Massachusetts, USA
- <sup>5</sup>Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany
- <sup>6</sup>German Center for Infection Research, Partner site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany
- <sup>7</sup>Department of Genetics, University of Cambridge, Cambridge, United Kingdom

AUTHOR ORCIDs

- Jody E. Phelan  <http://orcid.org/0000-0001-8323-7019>  
Sophia B. Georghiou  <http://orcid.org/0000-0003-0099-903X>  
Taane G. Clark  <http://orcid.org/0000-0001-8985-9265>  
Stefan Niemann  <http://orcid.org/0000-0002-6604-0684>  
Claudio U. Köser  <http://orcid.org/0000-0002-0232-846X>

FUNDING

Funder	Grant(s)	Author(s)
UK Research and Innovation	BBSRC BB/X018156/1, MRC MR/X005895/1, EPSRC EP/Y018842/1	Taane G. Clark
German Ministry of Health	SubSaharanSeqNet project (ZMVI1-2519GHP708)	Stefan Niemann
Deutsche Forschungsgemeinschaft	EXC 2167 Precision Medicine in Inflammation and the Research Training Group 2501 TransEvo, Leibniz Science Campus Evolutionary Medicine of the Lung	Stefan Niemann

## AUTHOR CONTRIBUTIONS

Viktória Szél, Conceptualization, Investigation, Writing – review and editing | Jody E. Phelan, Conceptualization, Investigation, Writing – review and editing | Sophia B. Georghiou, Investigation, Writing – review and editing | David L. Dolinger, Investigation, Writing – review and editing | Taane G. Clark, Resources, Writing – review and editing | Stefan Niemann, Resources, Writing – review and editing | Lilla K. Lőrinczi, Supervision, Writing – review and editing | Claudio U. Köser, Conceptualization, Investigation, Writing – original draft, Writing – review and editing

## ADDITIONAL FILES

The following material is available [online](#).

### Supplemental Material

**Supplemental material (AAC00265-25-s0001.docx).** Supplemental methods; Fig. S1.

**Table S1 (AAC00265-25-s0002.xlsx).** *ahpC*, *katG*, and *inhA* mutations in 11,954 lineage 4.1.2.1 genomes.

## REFERENCES

- Dean AS, Signol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, Köser CU, Gonzalez-Angulo LY, Tosas-Auget O, Ismail N, Tahseen S, Ama MCG, Skrahina A, Alikhanova N, Kamal SMM, Floyd K. 2020. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. *PLoS Med* 17:e1003008. <https://doi.org/10.1371/journal.pmed.1003008>
- World Health Organization. 2024. WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection. 3rd ed. <https://iris.who.int/handle/10665/376155>.
- Napier G, Campino S, Phelan JE, Clark TG. 2023. Large-scale genomic analysis of *Mycobacterium tuberculosis* reveals extent of target and compensatory mutations linked to multi-drug resistant tuberculosis. *Sci Rep* 13:623. <https://doi.org/10.1038/s41598-023-27516-4>
- World Health Organization. 2023. Catalogue of mutations in *Mycobacterium tuberculosis* complex and their association with drug resistance. 2nd ed. <https://iris.who.int/handle/10665/374061>.
- EuDiPia. 2019. EuDx MDR-TB detection kit
- ShengTing Medical Technology. 2022. *Mycobacterium* nucleic acid and *M. tuberculosis* drug resistance gene detection kits
- Ustar Biotechnologies. MultNAT MTC/MDR assay. Instructions for use. Version: A1
- Bang H, Park S, Hwang J, Jin H, Cho E, Kim DY, Song T, Shamputa IC, Via LE, Barry CE, Cho S-N, Lee H. 2011. Improved rapid molecular diagnosis of multidrug-resistant tuberculosis using a new reverse hybridization assay, REBA MTB-MDR. *J Med Microbiol* 60:1447–1454. <https://doi.org/10.1099/jmm.0.032292-0>
- Hu S, Li G, Li H, Liu X, Niu J, Quan S, Wang F, Wen H, Xu Y, Li Q. 2014. Rapid detection of isoniazid resistance in *Mycobacterium tuberculosis* isolates by use of real-time-PCR-based melting curve analysis. *J Clin Microbiol* 52:1644–1652. <https://doi.org/10.1128/JCM.03395-13>
- Xiamen Zeesan Biotech. MeltPro MDR-TB test kit (MMCA). VER. A/3
- Xiamen Zeesan Biotech. MDR-TB test kit (Sanity 2.0) VER. A/2
- Xiamen Zeesan Biotech. MTB/MDR test kit (Sanity 2.0). VER. A/1
- Yoo IY, Huh HJ, Kang O-K, Jhun BW, Koh W-J, Lee NY. 2019. Advantages of the AdvanSure MDR-TB GenoBlot assay containing disputed *rpoB* mutation-specific probes in a routine clinical laboratory setting. *Respir Med* 146:71–75. <https://doi.org/10.1016/j.rmed.2018.12.001>
- Kurbatova EV, Kaminski DA, Erokhin VV, Volchenkov GV, Andreevskaya SN, Chernousova LN, Demikhova OV, Ershova JV, Kaunetis NV, Kuznetsova TA, Larionova EE, Smirnova TG, Somova TR, Vasilieva IA, Vorobieva AV, Zolkina SS, Cegielski JP. 2013. Performance of Cepheid Xpert MTB/RIF and TB Biochip MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis. *Eur J Clin Microbiol Infect Dis* 32:735–743. <https://doi.org/10.1007/s10096-012-1798-0>
- Zimenkov DV, Kulagina EV, Antonova OV, Zhuravlev VY, Gryadunov DA. 2016. Simultaneous drug resistance detection and genotyping of *Mycobacterium tuberculosis* using a low-density hydrogel microarray. *J Antimicrob Chemother* 71:1520–1531. <https://doi.org/10.1093/jac/dkw015>
- Gagneux S. 2018. Ecology and evolution of *Mycobacterium tuberculosis*. *Nat Rev Microbiol* 16:202–213. <https://doi.org/10.1038/nrmicro.2018.8>
- Dhandayuthapani S, Zhang Y, Mudd MH, Deretic V. 1996. Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: characterization and inducibility of *ahpC* by peroxides in *Mycobacterium smegmatis* and lack of expression in *M. aurum* and *M. tuberculosis*. *J Bacteriol* 178:3641–3649. <https://doi.org/10.1128/jb.178.12.3641-3649.1996>
- Wilson TM, Collins DM. 1996. *ahpC*, a gene involved in isoniazid resistance of the *Mycobacterium tuberculosis* complex. *Mol Microbiol* 19:1025–1034. <https://doi.org/10.1046/j.1365-2958.1996.449980.x>
- Zhang Y, Dhandayuthapani S, Deretic V. 1996. Molecular basis for the exquisite sensitivity of *Mycobacterium tuberculosis* to isoniazid. *Proc Natl Acad Sci USA* 93:13212–13216. <https://doi.org/10.1073/pnas.93.23.13212>
- Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser JM. 1997. Analysis of the *oxyR-ahpC* region in isoniazid-resistant and -susceptible *Mycobacterium tuberculosis* complex organisms recovered from diseased humans and animals in diverse localities. *Antimicrob Agents Chemother* 41:600–606. <https://doi.org/10.1128/AAC.41.3.600>
- Kulkarni SG, Laurent S, Miotto P, Walker TM, Chindelevitch L, Nathanson C-M, Ismail N, Rodwell TC, Farhat MR. 2025. Multivariable regression models improve accuracy and sensitive grading of antibiotic resistance mutations in *Mycobacterium tuberculosis*. *Nat Commun* 16:2149. <https://doi.org/10.1038/s41467-025-57174-1>
- Vargas R, Freschi L, Spitaleri A, Tahseen S, Barilar I, Niemann S, Miotto P, Cirillo DM, Köser CU, Farhat MR. 2021. Role of epistasis in amikacin, kanamycin, bedaquiline, and clofazimine resistance in *Mycobacterium tuberculosis* complex. *Antimicrob Agents Chemother* 65:e0116421. <https://doi.org/10.1128/AAC.01164-21>
- Köser CU, Robledo J, Shubladze N, Schön T, Dolinger DL, Salfinger M. 2021. Guidance is needed to mitigate the consequences of analytic errors during antimicrobial susceptibility testing for TB. *Int J Tuberc Lung Dis* 25:791–794. <https://doi.org/10.5588/ijtld.21.0428>